Alkhamiss Abdullah Saleh
Department of Pathology, College of Medicine, Qassim University, Qassim, Saudi Arabia.
Int J Health Sci (Qassim). 2024 Nov-Dec;18(6):20-24.
The differentiation between reactive atypical changes and dysplasia/carcinoma in the daily cases of cholecystectomies is a routine histopathological challenge. Up to our knowledge, no immunohistochemical marker can definitely differentiate between these two changes. Many promising markers have been proposed to be helpful tools in this situation. One of them is B-cell lymphoma-2 (BCL-2) immunohistochemical stain. Therefore, this study aims to evaluate its usefulness as a marker that might be helpful in such challenging cases.
From the archive of the histopathology laboratories of Qassim University Medical City and King Fahad Specialist Hospital in Qassim, five dysplastic/neoplastic gallbladder cases were collected (in the shape of formalin-fixed, paraffin-embedded blocks) as well as five cholecystitis with reactive atypical changes cases. Two slides from each block were prepared: One was stained with H&E and the other was stained immunohistochemically with BCL-2. The slides were evaluated by two histopathologist consultants in the same sitting using multiheaded microscope to confirm the original diagnosis and to evaluate the BCL-2 staining.
Five dysplastic/carcinoma cases and five cholecystitis with reactive atypia were collected. The original diagnoses were confirmed by two pathologists. They also confirmed that all the BCL-2 stained slides (with the exception of one reactive case) were negative for BCL-2 immunohistochemical stain.
BCL-2 immunohistochemical stain is not a promising marker in the differentiation between reactive epithelium and dysplasia/carcinoma in the gallbladder.
在日常胆囊切除术病例中,鉴别反应性非典型改变与发育异常/癌是一项常规组织病理学挑战。据我们所知,尚无免疫组化标志物能明确区分这两种改变。许多有前景的标志物已被提出可在此种情况下作为有用工具。其中之一是B细胞淋巴瘤-2(BCL-2)免疫组化染色。因此,本研究旨在评估其作为一种可能有助于此类具有挑战性病例的标志物的效用。
从卡西姆大学医学城和卡西姆法赫德国王专科医院的组织病理学实验室存档中,收集了5例发育异常/肿瘤性胆囊病例(以福尔马林固定、石蜡包埋块的形式)以及5例伴有反应性非典型改变的胆囊炎病例。从每个包埋块制备两张玻片:一张用苏木精-伊红(H&E)染色,另一张用BCL-2进行免疫组化染色。两位组织病理学顾问在同一次会诊中使用多头显微镜对玻片进行评估,以确认原诊断并评估BCL-2染色情况。
收集了5例发育异常/癌病例和5例伴有反应性异型增生的胆囊炎病例。两位病理学家确认了原诊断。他们还确认,所有BCL-2染色的玻片(除1例反应性病例外)BCL-2免疫组化染色均为阴性。
BCL-2免疫组化染色在胆囊反应性上皮与发育异常/癌的鉴别中并非一种有前景的标志物。